Literature DB >> 11383481

Glucagon is an ACTH secretagogue as effective as hCRH after intramuscolar administration while it is ineffective when given intravenously in normal subjects.

E Arvat1, B Maccagno, J Ramunni, R Giordano, L DiVito, F Broglio, M Maccario, F Camanni, E Ghigo.   

Abstract

It is widely accepted that glucagon stimulates GH, ACTH and cortisol release in humans, though the mechanisms underlying these effects are unclear. Aim of the present study was to evaluate the stimulatory effect of intramuscolar (i.m.) and intravenous (i.v.) glucagon (GLU) administration on ACTH, cortisol (F) and GH release in normal adult subjects and to compare its effect on hypothalamo-pituitary adrenal (HPA) axis with that of hCRH. To this goal, in 6 normal young women (26-32 yrs, 50-58 kg) we studied the ACTH and F responses to either i.m. or i.v. GLU (1 mg, approximately 0.017 mg/kg in subjects of 54.1 +/- 1.6 kg) administration as well as to i.v. hCRH (2.0 micrograms/kg) or placebo administration. The GH and glucose variations after GLU administration were also studied. I.v. GLU did not modify the spontaneous decrease of ACTH and cortisol levels observed after placebo. Conversely, i.m. GLU elicited clear-cut ACTH and F responses (peak vs baseline, mean +/- SEM: 53.0 +/- 15.2 vs 19.0 +/- 1.5 pg/ml, p < 0.05 and 222.3 +/- 23.8 vs 158.3 +/- 7.0 micrograms/l, p < 0.05) which were higher than those recorded after hCRH (28.1 +/- 4.6 vs 17.4 +/- 3.1 pg/ml, p < 0.02 and 182.7 +/- 22.8 vs 114.8 +/- 12.3 micrograms/l p < 0.02), though this difference did not attain statistical significance. Also GH rise was recorded after i.m. but not after i.v. GLU administration (11.6 +/- 3.4 vs 3.3 +/- 0.7 micrograms/l, p < 0.05). Thirty min after both i.v. and i.m. GLU administration glucose levels showed a similar increase followed by similar decrease. The intramuscular administration of GLU induced negligible side-effects in some subject (mild and transient nausea) which, on the contrary, were clear in all subjects after its intravenous administration (nausea, vomiting, tachycardia). In conclusion, glucagon "per se" is not an ACTH, cortisol and GH secretagogue. After intramuscular administration glucagon is a stimulus of HPA axis at least as effective as hCRH. The mechanisms underlying the ACTH, cortisol and GH responses to i.m. glucagon unlikely include glucose variations or stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11383481     DOI: 10.1023/a:1011451710004

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  21 in total

1.  Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.

Authors:  P J Larsen; M Tang-Christensen; D S Jessop
Journal:  Endocrinology       Date:  1997-10       Impact factor: 4.736

2.  Growth-hormone release by glucagon.

Authors:  M L Mitchell; M J Byrne; J Silver
Journal:  Lancet       Date:  1969-02-08       Impact factor: 79.321

3.  [Discussion of Messrs P. Lefebvre and A. Luyckx lecture: "Glucagon and energetic substrates" published in the Bulletin, vol. 128, fasc. 2, 1973, pp. 163-185].

Authors:  J Lecomte; P Lefebre
Journal:  Bull Acad R Med Belg       Date:  1974

4.  Effect of exogenous glucagon on pituitary polypeptide hormone release.

Authors:  R L Eddy; A L Jones; R M Hirsch
Journal:  Metabolism       Date:  1970-10       Impact factor: 8.694

5.  The early rise of plasma growth hormone (HGH) and immunoreactive insulin (IRI) in children following intravenous glucagon.

Authors:  G Snodgrass; L Stimmler
Journal:  J Clin Endocrinol Metab       Date:  1972-02       Impact factor: 5.958

6.  Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST).

Authors:  S M Orme; A Price; A P Weetman; R J Ross
Journal:  Clin Endocrinol (Oxf)       Date:  1998-12       Impact factor: 3.478

7.  Plasma glucose, non-esterified fatty acid, insulin and growth hormone response to glucagon in the newborn.

Authors:  R D Milner; A D Wright
Journal:  Clin Sci       Date:  1967-04       Impact factor: 6.124

8.  The central corticotropin-releasing factor and glucagon-like peptide-1 in food intake of the neonatal chick.

Authors:  M Furuse; M Matsumoto; N Saito; K Sugahara; S Hasegawa
Journal:  Eur J Pharmacol       Date:  1997-11-27       Impact factor: 4.432

9.  Hypoglycemia: a potent stimulus to secretion of growth hormone.

Authors:  J ROTH; S M GLICK; R S YALOW
Journal:  Science       Date:  1963-05-31       Impact factor: 47.728

10.  Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity.

Authors:  E Ghigo; E Bartolotta; E Imperiale; J Bellone; G Cardinale; G Aimaretti; M R Valetto; V Cherubini; M Maccario; D Cocchi
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

View more
  5 in total

Review 1.  The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis.

Authors:  James Frampton; Chioma Izzi-Engbeaya; Victoria Salem; Kevin G Murphy; Tricia M Tan; Edward S Chambers
Journal:  Int J Obes (Lond)       Date:  2022-09-19       Impact factor: 5.551

2.  Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.

Authors:  F Tassone; S Grottoli; R Rossetto; B Maccagno; C Gauna; R Giordano; E Ghigo; M Maccario
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

Review 3.  Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis.

Authors:  Zuleyha Karaca; Ashley Grossman; Fahrettin Kelestimur
Journal:  Rev Endocr Metab Disord       Date:  2021-03-26       Impact factor: 6.514

4.  The stimulatory effects of glucagon on cortisol and GH secretion occur independently from FGF-21.

Authors:  Ilyas Akkar; Zuleyha Karaca; Serpil Taheri; Kursad Unluhizarci; Aysa Hacioglu; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2021-09-25       Impact factor: 3.633

5.  A possible primary cause of cancer: deficient cellular interactions in endocrine pancreas.

Authors:  Maurice Israël
Journal:  Mol Cancer       Date:  2012-09-06       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.